New Delhi: Serum Institute of India (SII) has sought approval from the country’s drug regulator for a phase III trial of its anti-coronavirus vaccine Covovax as a booster dose for adults. The Drug Controller General of India (DCGI) on December 28 approved the emergency use of Kovovax on adults. However, this vaccine has not yet been included in the vaccination campaign.
ਯੂਕਰੇਨ ’ਚ ਫਸੇ ਭਾਰਤੀ ਬੱਚੇ, ਪੈਦਾ ਹੋਇਆ ਵੱਡਾ ਖ਼ਤਰਾ
Prakash Kumar Singh, director of government and regulatory affairs at SII, had submitted an application to the DCGI last week for permission for the third phase of the trial. The booster dose will be tested on adults who have taken Covishield or a second dose of Covaccine three months ago. In this, the safety and effectiveness of the vaccine will be assessed.
